|
Five-year overall survival and relapse-free survival of 69 patients who received Paclitaxel/Carboplatin |
||||
| 5y OS (95% CI) |
P* |
5y RFS (95% CI) |
P* |
|
|
|
||||
| All patients (n = 69) |
87% (78–96) no of deaths: 7 |
79% (69–89) no of relapses: 14 |
||
|
|
||||
| Stage |
.81 |
.28 |
||
| Ia, Ib (n = 16) |
94% (82–100) No of deaths: 1 |
93% (79–100) No of relapses: 1 |
||
| Ic, II (n = 53) |
86% (75–97) No of deaths: 6 |
78% (66–90) No of relapses: 13 |
||
|
|
||||
| Grade |
.88 |
.30 |
||
| 1 (n = 12) |
92% (76–100) No of deaths: 1 |
92% (76–100) No of relapses: 1 |
||
| 2,3 (n = 54) |
86% (75–97) No of deaths: 6 |
78% (66–90) No of relapses: 13 |
||
|
|
||||
| Ia/Ib OR grade 1 (n = 28) |
93% (83–100) No of deaths: 2 |
.58 |
92% (82–100) No of relapses: 2 |
.03 |
| Ic/II AND grade2/3 (n = 39) |
84% (71–97) No of deaths: 5 |
73%(58–88) No of relapses: 12 |
||
|
*p values estimated with log rank test | ||||
Bamias et al. BMC Cancer 2006 6:228 doi:10.1186/1471-2407-6-228 |
||||